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Abstract 
Aim: Meta-analyses indicate positive effects of both antipsychotic and cognitive-behavioural 
interventions in subjects clinically at high risk (CHR) for psychosis in terms of a delay or 
prevention of psychotic disorders. However, these effects have been limited regarding social 
functioning and the relative efficacy of both types of interventions remains unclear. 
Furthermore, neuroprotective substances seem to be a promising alternative agent in 
psychosis-prevention as they are associated with few and weak side-effects.  
 
Methods: In this multi-centre randomised controlled trial (RCT), we investigate the effects of 
two interventions on transition to psychosis and social functioning: (1) an Integrated Preventive 
Psychological Intervention (IPPI) including stress-/symptom-management and social cognitive 
remediation; (2) N-acetyl-L-cysteine (ACC) as a pharmacological intervention with 
glutamatergic, neuroprotective and anti-inflammatory capabilities. This is a double-blind, 
placebo-controlled RCT with regard to ACC and a single-blind RCT with regard to IPPI using 
a 2×2-factorial design to investigate the individual and combined preventive effects of both 
interventions. To this aim, a total of 200 CHR-subjects will be randomised stratified by site to 
one of four conditions: (1) IPPI and ACC; (2) IPPI and Placebo; (3) ACC and Psychological 
Stress Management; (4) Placebo and Psychological Stress Management. Interventions are 
delivered over 26 weeks with a follow-up period of 12 months. 
 
Conclusion: This paper reports on the rationale and protocol of an indicated prevention trial 
to detect the most effective and tolerable interventions with regard to transition to psychosis 
as well as improvements in social functioning and to evaluate the synergistic effects of these 
interventions. 
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1. Introduction 
Psychotic disorders are associated with huge individual and societal burden. Therefore, they 
are among the most expensive brain-related disorders in Europe (Vigo et al., 2016; Wittchen 
et al., 2011). To fight these detrimental outcomes, indicated prevention approaches have been 
developed to target individuals at clinical high risk (CHR) for psychosis (Fusar-Poli et al., 2013; 
Schultze-Lutter et al., 2015).  
 
1.1 Need for integrated preventive psychological interventions 
Most studies have focused on reducing risk-symptoms by improving symptom-management 
and found significantly larger effects on transition rates at 6- to 48-month follow-up than control 
conditions (Schmidt et al., 2015; van der Gaag et al., 2013). However, social functioning is an 
important but neglected outcome given that substantial functional impairments are already 
present in CHR-subjects, often worsen until transition to psychosis and are even predictive of 
it (Addington et al., 2017; Fusar-Poli et al., 2015; Ruhrmann et al., 2010; Velthorst et al., 2017). 
Current approaches did not produce significantly larger effects on social functioning than 
control conditions (Schmidt et al., 2015; van der Gaag et al., 2013). One reason for this may 
be that these approaches were mainly designed to prevent transition to psychosis. Therefore, 
they were based on cognitive-behavioural therapy (CBT) techniques that are well-established 
for treatment of positive symptoms of psychosis. Thus, novel interventions are needed to 
directly target factors modulating social functioning, such as social cognition (Cotter et al., 
2017; Glenthøj et al., 2016; Schmidt et al., 2011). Social cognition as the mental operations 
underlying social interactions comprises the following domains: social and emotional 
perception, Theory of Mind and social attribution styles (Green et al. 2008; Pinkham et al., 
2016). These domains are already impaired in CHR-subjects (Lee et al., 2015; van 
Donkersgoed et al. 2015). Although the need of social-cognitive remediation for CHR-subjects 
has also been highlighted in recent reviews (Glenthøj et al., 2017; Statucka & Walder, 2013), 
there is still a lack of studies evaluating the efficacy of such approaches.  
Moreover, current prevention approaches often neglect the fact that, in addition to the markedly 
increased risk for developing psychosis, CHR-individuals already suffer from multiple mental 
problems, such as increased levels of distress and poor stress-management skills (Schmidt et 
al., 2014). Therefore, in line with stress-vulnerability models (Gispen-de Wied et al., 2002; 
Nuechterlein & Dawson, 1984), psychological interventions to improve stress-management 
should also be part of psychosis prevention programs.  
 
 
 
1.2 Need for novel neuroprotective interventions 
Preventive interventions require a most favourable risk-benefit ratio. However, antipsychotics 
used in most pharmacological trials in this field showed unfavourable side-effects (Ruhrmann 
et al., 2012). Therefore, potential neuroprotective substances with only few and weak side-
effects seem promising. One such neuroprotective agent is N-acetyl-L-cysteine (ACC), which 
targets dysfunctional glutamatergic neurotransmission, shown to be altered in CHR-subjects 
(Treen et al. 2016). ACC can elevate brain glutathione (GSH), a major cellular redox regulator 
and anti-oxidant protecting cells from the damages of reactive oxygen species (Meister & 
Anderson, 1983). Brain GSH levels have shown to be decreased in the medial prefrontal 
cortex, in the caudate region and cerebrospinal fluid of drug-naive patients with schizophrenia 
(Do et al., 2000; Yao et al., 2006). GSH deficiency aggravates neuronal oxidative stress linked 
to abnormal metabolism of dopamine and glutamate in schizophrenia (Castagné et al., 2004; 
Smythies, 1997). Polymorphisms of genes involved in GSH synthesis, leading to suppressed 
protein expression and reduced GSH levels, have also been associated with an enhanced risk 
for schizophrenia (Gysin et al., 2007; Tosic et al., 2006). ACC increases plasma cysteine 
levels, thus filling up depleted GSH levels and preventing GSH depletion (Kamboj et al., 2006). 
In support of this, ACC has been shown to be superior to placebo with regard to symptomatic, 
cognitive and functional improvements in trials in patients with schizophrenia (Berk et al., 2008; 
Lavoie et al., 2007; Rapado-Castro et al., 2017; Retsa et al., 2018). The fact that the 
mechanisms of action of ACC overlap with the GSH-linked pathophysiology of schizophrenia 
and CHR-states as well as its benign tolerability and safety profile bear the promise to prevent 
transition to psychosis by augmenting neuronal GSH production. 
 
1.3 Relative and combined interventions effects 
ACC is supposed to optimise the effects of psychological interventions (Deepmala et al. 2015). 
However, with the exception of one randomised controlled trial (RCT) (McGorry et al., 2013), 
all pharmacological interventions so far were also offered in combination with some kind of 
psychological intervention, and CHR-subjects in psychological trials were also allowed to take 
medication (Schmidt et al., 2015). Therefore, positive effects can neither be clearly attributed 
to one intervention nor do these studies allow any conclusions about the additive effect of both 
forms of interventions. Thus, multiple head-to-head comparisons are necessary to investigate 
the relative and combined efficacy of psychological and pharmacological interventions. 
Against this background, we aim to investigate the individual and combined preventive effects 
of two interventions on transition rates and improvements on social functioning in CHR-
subjects: 1. of an Integrated Preventive Psychological Intervention (IPPI) focusing on 
symptom-/stress-management and social-cognitive remediation and 2. ACC as a 
pharmacological intervention with glutamatergic, neuroprotective and anti-inflammatory 
capabilities. 
 
2. Methods 
2.1 Design 
This study is a 2×2-factorial trial (see Figure 1): A double-blind, placebo-controlled RCT with 
regard to ACC and a single-blind RCT with regard to IPPI. This serves to investigate the 
individual and combined preventive effects with ACC and IPPI as the experimental condition 
while placebo (Plc) and psychological stress-management (PSM) serve as the control 
condition (see Figure 1). Consequently, a total of 200 CHR-subjects will be randomised 
(1:1:1:1) stratified by site to one of four conditions, i.e. 50 participants per condition: (1) IPPI 
and ACC; (2) IPPI and Plc; (3) ACC and PSM; (4) Plc and PSM. Random assignment is 
implemented as a 24-7 internet service (ALEA; FormsVisionBV, Abcoude, NL; 
http://www.formsvision.com/). Allocation sequences are made from permuted blocks of varying 
length. Randomisation results are given on screen and are sent by e-mail to authorised 
members of staff. Interventions will be provided for 26 weeks including a follow-up period of 
12 months with major assessments at baseline (week -4 to 0), beginning of intervention(s) after 
randomisation (week 0), at week 12, at the end of intervention(s) (week 26), at 1-year follow-
up (week 52) and end of follow-up (week 78) (see Table 1).  
 
- Please FIGURE 1 and TABLE 1 here - 
 
2.2 Setting 
The project with the acronym ESPRIT-B1 (ClinicalTrials.gov Identifier: NCT03149107) is part 
of the multi-trial "Enhancing Schizophrenia Prevention and Recovery through Innovative 
Treatments" consortium (coordinator: Andreas Meyer-Lindenberg, Mannheim). ESPRIT is 
funded by the German Federal Ministry of Education and Research (BMBF) as part of the 
German Research Network for Mental Disorders and aims at developing and evaluating 
innovative interventions to (a) prevent transition to schizophrenia in high-risk individuals, (b) 
enhance symptomatic and functional recovery in schizophrenia patients in the early phase of 
the illness, and (c) implement these interventions in clinical practice. ESPRIT-B1 is a multi-
centre study involving 11 centres in Germany with established early psychosis centres: RWTH 
Aachen, RH-FK Alzey, Charité and Vivantes Clinic Berlin, UK Bonn (coordinating centre for 
ACC), UK Düsseldorf, MHH Hannover, UK Köln (coordinating centre for IPPI), ZI Mannheim, 
LMU München and UK Tübingen.  
Study therapists trained in cognitive-behavioural therapy took part in a 2-day workshop on IPPI 
and PSM before the begin of the study based on the respective manuals. All parts of this 
workshop are also available as podcasts and arising problems were additionally discussed in 
telephone meetings following the workshop. Regular supervision is provided for raters and 
therapists separately in form of a monthly 1-hour telephone conference and additionally on 
individual basis via telephone or skype. Each session is audiotaped and rated by two 
independent individuals based on a well-established fidelity checklist (Haddock, 2002). All 
participating centres obtained ethical approval by the respective regulatory authority based on 
the respective trial protocol (January 2017).  
 
2.3 Sample 
Inclusion, exclusion and withdrawal criteria of this study are shown in Table 2 and are in line 
with previous studies (Klosterkötter et al., 2005). Participants had to meet any ultra-high risk 
or basic symptom criterion as assessed by the as assessed by the Structured Interview for 
Psychosis-Risk Syndromes (SIPS 5.0; McGlashan et al., 2010) and the Schizophrenia 
Proneness Instrument, Adult version (SPI-A; Schultze-Lutter et al., 2007). SIPS and SPI-A 
have shown good interrater-reliability and construct-validity with good test–retest reliability 
across short periods of time and assessment modes (McGlashan et al., 2001; Schultze-Lutter 
et al., 2012; Michel et al., 2014). 
 
- Please TABLE 2 here - 
 
2.4 Interventions 
2.4.1 N-acetyl-L-cysteine (ACC) and placebo (Plc) 
Both ACC and Plc are provided as two capsules à 500 mg twice a day, yielding a total dosage 
of 2000 mg per day. Dosage and mode of intervention were chosen in accordance with a 
recent trial (Berk et al. 2008) supporting the safety and efficacy of ACC in schizophrenia 
patients.  
 
2.4.2 Integrated Preventive Psychological Intervention (IPPI) 
IPPI was developed in a manualised form with the aim (1) to provide adaptive strategies and/or 
to reduce maladaptive strategies to cope with stressors efficiently; (2) to enhance 
understanding of and coping with current and future CHR-symptoms; (3) to provide strategies 
to improve social-cognitive information-processing and social competencies by optimising 
encoding-processes of social signals and by reducing social-cognitive biases. Therefore, IPPI 
comprises four main modules: (1) disorder-related knowledge, (2) stress-management, (3) 
symptom-management and (4) social-cognitive remediation (see Table 3). They will be 
targeted in 22 sessions in an individual setting as single sessions lasting 50 or 90 minutes. 
The first 21 sessions are scheduled weekly with one booster-session two weeks after the last 
session. Every module is organised in such a way to increase therapy motivation by activating 
an individual’s resources, personalising contents through selection of the most relevant 
strategies for each individual and by facilitating experiental learning using multi-sensory 
materials (e.g. audios, videos of real-life situations, cartoons). Generalisation of effects is 
enhanced in every module and in particular in the booster-session by elaborating on the 
relevance of the respective target domain for everyday-life, building upon and optimising 
already existing strategies, discussing how to deal with potential barriers and by practising new 
skills in the natural environment between sessions as homework.  
- Please Table 3 here –  
 
2.4.3 Psychological stress-management (PSM) 
PSM is based on the well-established relevance of stress and poor coping on the development 
of psychotic symptoms (Gomes & Grace, 2017) and aims to improve coping with stressful 
experiences. It is carried out in an individual setting as an active, manualised control condition 
to ensure that all participants are offered an intervention and potentially benefit from their study 
participation. PSM comprises 11 sessions à 50 minutes. The first 10 sessions are offered bi-
weekly; the last session is scheduled two weeks after session 10. The sessions comprise the 
following content: Psychoeducation with a narrower model of psychosis development focusing 
on the role of stress (session 1-3) and stress-management (session 4-10) followed by a closure 
and booster session (session 11).  
 
2.4.4 Prior and concomitant interventions 
All previous interventions to manage the trial specific illness are documented in an electronic 
case report form (CRF). With regard to indications other than the trial specific illness, all 
previous interventions are allowed and documented in the CRF for the past 3 months before 
the beginning of the trial. With regard to concomitant interventions, the short-term 
administration of lorazepam or oxazepam for acute agitation as well as zolpidem, zopiclon or 
temazepam for sleep disturbances is allowed. Any intake of antipsychotic and/or mood-
stabilising medication and/or pregabalin and/or the use of antitussives and nitroglycerin are 
prohibited during the whole trial-period. All concomitant psychological and/or pharmacological 
interventions for other indications at the discretion of the investigator are administered in line 
with current treatment guidelines and documented in the subject`s study record and CRF.  
 
2.4.5 Blinding of interventions 
Packaging, appearance, colour and taste of the capsules of ACC and Plc are identical to 
ensure blinding. To maintain blindness of raters, they have access to the (anonymous) patient- 
and therapy-ID only. Furthermore, IPPI and PSM will be carried out independently from 
assessors, who are kept unaware of the treatment allocation during all times of the trial. To 
avoid any form of communication between therapists and assessors, they are not allowed to 
talk about study subjects with each other and have separate offices as well as study 
procedures. Study subjects are instructed not to disclose aspects of their intervention to the 
assessors. Assessors are asked to record any loss of masking of treatment allocation and are 
asked to guess the allocation. Success of blinding is reported by the ratio of agreements 
between guessed allocation and real allocation.  
 
 
3. Hypotheses 
1. Both ACC and IPPI produce significant effects on transition rates to psychosis and 
significant improvements in social functioning as primary outcomes compared to 
control conditions.  
2. Both ACC and IPPI produce significant improvements in neuro- and social-cognitive 
domains as secondary outcomes relative to control conditions. 
3. Combined effects of ACC and IPPI on primary and secondary outcomes are 
significantly larger than those of ACC or IPPI alone.  
4. IPPI is hypothesised to produce significantly larger effects on social cognition and 
social functioning than ACC and PSM. 
5. Comparable tolerability is hypothesised for ACC and IPPI. 
 
4. Study outcomes 
4.1 Primary study outcomes 
Primary outcome are both transition to psychosis defined as the presence of at least one 
psychotic symptom for at least one week and social functioning after 18 months (see Table 1).  
 
4.2 Secondary study outcomes 
As secondary outcomes, we investigate effects on remission of CHR-criteria (i.e. attenuated 
psychotic symptoms (APS), brief intermittent psychotic symptoms (BIPS) and/or cognitive 
basic symptoms (cognitive disturbances, COGDIS), decrease in overall positive, negative and 
disorganisation symptoms and depressive symptoms (see Table 1). Furthermore, changes in 
neuro- and social-cognitive domains are assessed including speed of processing, attention, 
verbal learning and memory, executive functions, emotion recognition, social attributions and 
theory of mind. Additional variables are shown in Table 1. The following treatment-related 
variables will be assessed: dispense/return of study medication, reasons for study 
discontinuation, self-reported treatment adherence and reported expectations as well as 
evaluation regarding treatment. Moreover, safety and tolerability of interventions are evaluated 
by: (1) Neurologic and general examination (medical history, weight); (2) Identification of 
adverse events and (3) laboratory assessments including haematology/chemistry panels, a 
blood/urine pregnancy test at baseline and additionally an urine pregnancy test during the 
whole intervention period in case of suspected pregnancy and urine drug toxicology screens 
(in case of positive assessment of transition). Adverse events (AEs) will be summarized by 
MedDRA code, relatedness, seriousness and severity. Any AE relevant for the evaluation and 
analysis of the clinical trial has to be documented in the CRF. Every serious adverse event 
(SAE) that occurs between the first intake of study medication and 30 days after the last 
administration of study medication must be documented in the CRF and on the SAE report 
form. The investigator has to report any SAE within 24 hours and every pregnancy detected 
during the clinical trial to the Clinical Trials Centre Cologne. All cases of Suspected Unexpected 
Serious Adverse Reactions (SUSARs) during the study has to be reported by the sponsor or 
Principal/Coordinating Investigator to the responsible supreme federal authority and the 
respective Ethics Committee and to all clinical trials investigators of the same active 
substance.” 
4.3 Additional study outcomes 
Additional outcomes (see Table 1) are the following: (Functional) magnetic resonance imaging 
(fMRI) is carried out to investigate functional and structural abnormalities while performing 
psychological tasks with the aim to detect differences between converters and non-converters. 
Magnetic resonance spectroscopy (MRS) and blood tests are administered to determine 
whether receiving ACC effectively elevates glutathione levels. Experience sampling is carried 
out via smartphones at the beginning and after the intervention to collect participants’ 
responses to questions regarding mood, symptoms, social context, stress, sleep and current 
location using geo-localising. Furthermore, health economic analyses are conducted to 
evaluate the cost-effectiveness of these interventions. Biographical, neuropsychological and 
psychopathology data are clustered using multivariate cluster analysis (RDoC), which yields 
subgroups of individual variation across these variables within the population under study. 
Each subject’s likelihood of belonging to such a subgroup is used to explore differences in 
intervention effects as a function of syndrome constellations. Faecal samples are taken for 
molecular characterisation using 16S rRNA gene sequencing to investigate whether 
aberrations in microbial community structure and function predict transition to psychosis. 
Additionally, biobanking (genetics, epigenetics and proteomic) is used to evaluate whether 
aberrations predict a CHR-state or transition to psychosis. 
 
5. Statistical analyses 
5.1 Power 
Based on recent publications (Schultze-Lutter et al., 2015), we assume a transition risk of 
about 20% within 18 months. We expect a relative reduction in transition risk of 80% (Schmidt 
et al., 2015; van der Gaag et al., 2013), i.e. from 20% to 4%. To detect this difference with 80% 
power at two-sided level 2.5% (i.e. Bonferroni-corrected for two comparisons), an uncorrected 
chi-square test needs 77 subjects per group (IPPI yes vs. no; ACC yes vs. no). Using the actual 
time-to-event, the power of corresponding hypothesis tests (i.e. log-rank test, Cox regression) 
is expected to be slightly higher (Pocock, 1983). To compensate for the influence of about 25% 
drop-out, 100 CHR-subjects per group (i.e. 200 CHR-subjects in total, 50 per cell) will be 
included (see Figure 1). 
 
5.2 Data management 
The data management and monitoring infrastructure will be supplied by the Clinical Trials 
Centre Cologne including a firewall and daily backup system. Data will be entered online at the 
trial sites. All changes made to the data are documented in an audit trail. After completion and 
cleaning of data, the database is locked and the data are stored and exported for statistical 
analysis by the Clinical Trials Centre. 
 
5.3 Data analyses 
The full analysis set will be based on the intention-to-treat principle. The primary endpoint 
“transition within 18 months” will be analysed by time-to-event methods, i.e. Cox regression 
with main effects ACC, IPPI, age and gender; no interactions. To guard against type I error 
inflation, the 𝑝𝑝-values of the Wald statistics will be corrected for two comparisons. Hazard 
ratios and corresponding 97.5% confidence intervals will be determined. The proportional 
hazards assumption will be tested by introducing time-dependent covariates. Incomplete 
observations will be censored. Bias due to possibly informative censoring will be addressed in 
a sensitivity analysis by inverse probability weighting (IPW) (Cole & Hernan, 2004). The co-
primary outcome variables improvement of social functioning after 18 months will be analysed 
using mixed models for repeated measures (MMRM; fixed effects baseline, ACC, IPPI, time, 
ACC*time, IPPI*time; ARH1 covariance structure) with corresponding contrasts. Patterns of 
missing values will be investigated and the impact of various strategies for handling the missing 
values will be explored in a sensitivity analysis. Subgroup analyses will be done by centre and 
gender including exploration of possible interactions with interventions. Secondary outcomes 
will be analysed either by time-to-event methods, mixed models for repeated measures 
(MMRM) or using generalised estimating equations (GEEs) to describe and evaluate 
differences between groups and changes over time. Any clustering effects due to same care 
providers and centres will be investigated in sensitivity analyses (Boutron et al., 2008).  
 
6. Discussion 
This paper presents the study rationale and methodology of a large-number multi-centre 
prevention study in CHR-subjects. The study includes two different types of novel 
interventions: An Integrated Preventive Psychological Intervention (IPPI) with special 
emphasis on social cognition to complement and broaden current cognitive-behavioural 
intervention approaches and a novel pharmacological agent (ACC) with potential 
neuroprotective effects through its impacts on dysfunctional glutamatergic neurotransmission. 
The 2×2-factorial design of the study is intended to detect beneficial combinations of these 
interventions on several outcomes encompassing transition rate, social functioning, risk- and 
general symptoms, social-cognitive as well as neuropsychological performance and overall 
tolerability of these interventions. Together with additional data on potential biomarkers and 
neurobiological mechanisms, our results may support efforts to further personalise 
interventions for CHR-patients by matching intervention techniques to individual risk 
constellations and mechanisms of change. Potential limitations of this trial include the large 
number of assessments and exclusion criteria, which may pose difficulties to the recruitment-
process, and the overlap of contents between IPPI and PSM. Taken together, this trial is 
expected to provide new and well tolerated interventions, thus helping to lower the individual 
and societal burden of psychotic disorders.  
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Table 1. Schedule of assessments 
Instrument Domain 
Baseline Intervention-period Follow-up 
Weeks 
-4 to 0 0 2 4 6 8 10 12 14 16 18 22 26 30 39 52 65 78 
Psychometric assessments 
SIPS 5.0 Ultra-high risk 
criteria; negative, 
positive, 
disorganized and 
general symptoms  
 X  X  X  X     X   X  X 
SIPS (5.0), P-scale Transition to 
psychosis 
X X  X  X  X  X  X X X X X X X 
SPI-A Basic symptoms  
 
 X  X  X  X     X   X  X 
SOFAS Social and 
occupational 
functioning 
X       X     X   X  X 
FROGS Functional 
recovery in daily 
and social life 
X       X     X   X  X 
GFsocial and GFrole Social and school 
or work 
functioning  
X X      X     X  X X X X 
BNSS Negative 
symptoms 
X            X   X  X 
TPA Identification of 3 
main problems 
 X X X X X X X X X X X X  X X X X 
M.I.N.I 6.0 Diagnostic 
screening, Axis-I 
diagnosis 
X            X   X  X 
Qustions about current 
substance use  
Substance use 
behaviour X X  X  X  X  X  X X X X X X X 
BSI-53 Symptom level 
and distress 
X                  
CISS-24 Coping strategies X            X   X  X 
ESPRIT-WHO-QUOL Health-related 
quality of life 
X            X   X   
FETZ Chart of Life Events Current life-events 
and evaluation 
X       X     X   X  X 
CTQ Childhood abuse 
and neglect 
X                  
RSA Resilience X            X   X  X 
ISMI Stigma X            X   X  X 
16-NFCS Need for closure X            X   X  X 
ABF Daily hassles  X           X   X  X 
FKK Self-efficacy and 
locusof control 
X            X   X  X 
ISK-K Social skills X            X   X  X 
MASC Social Cognition, 
Theory of Mind 
X            X   X  X 
PoFA Social cognition, 
emotion 
recognition 
X            X   X  X 
SAT-MC Social cognition, 
social attribution 
X            X   X  X 
TMT A & B Speed of 
processing, 
executive 
functions 
X            X   X  X 
AVLT Verbal learning 
and memory 
X            X   X  X 
DSST Speed of 
processing 
X            X   X   
DS Verbal memory  X            X   X   
MWT-B Premorbid 
intelligence 
X                  
WHO Disability assessment 
schedule 
Disability 
X                  
Safety and tolerability assessments                   
Neurologic and general examination X            X      
Weight and hight X            X      
Pre-intervention symptoms (UKU symptom-list) X X                 
Adverse Events (UKU symptom-list)  X   X   X   X  X X     
CDSS, complete X       X     X   X  X 
CDSS, items 1,2,8,9  X X X X X X  X X X X  X X  X  
Laboratory assessments 
Haematology/chemistry panels X    X        X      
Urine/blood pregnancy test  X                  
Urine pregnancy test  X2 X
2 X2 X2 X2 X2 X2 X2 X2 X2 X2 X2      
Urine drug toxicology screen X X3  X3  X3  X3  X3  X3 X3 X3 X
3 X3 X3 X3 
Treatment-related  assessments 
Psychiatric and medical history X                  
Prior medication  X                 
Concomitant treatment  X  X   X   X   X X X X X X 
Dispense/return study medication  X   X   X   X  X      
Reasons for study discontinuation X X X X X X X X X X X X X X X X X X 
Self-reported treatment adherence     X   X   X  X      
DAI-10 X       X     X      
PATHEV X  X     X     X      
Protocol of psychological interventions (therapist)  X X X X X X X X X X X X      
Treatment allocation assumption (rater)  X  X  X  X  X  X X X X X X X 
Additional assessments 
MRI X            X      
MRS – Blood sample (MRS genetics) X            X      
Stool sample for 
Microbiome 
X            X   X   
Experience sampling  
(EMA) 
X X           X X     
Health economic analyses (MRV; WHO-Qol-Bref) X            X   X   
Biobanking (blood and saliva samples) X            X     X 
RdOc  X                  
Abbreviations: ABF, Daily Stress Inventory (Traue et al., 2005); AVLT, Auditory Verbal Learning Test (et al.,1997; Helmstadter et al., 2001Muller); 
BNSS, Brief Negative Syndrome Scale (Strauss et al., 2012); BSI-53, Brief Symptom Inventory-53 (Derogatis & Melisaratos, 1983); CDSS, Calgary 
Depression Scale (Addington et al., 1992); CISS-24, Coping Inventory for Stressful Situations (Endler & Parker, 1990); CTQ, Childhood Trauma 
Questionnaire (Scher et al., 2001); DAI; Drug Attitude Inventory (Hogan et al., 1983; Nielsen et al., 2002); DS, Digit Span (Petermann & Petermann, 
2010); DSST, Digit Symbol Substitution Test (Petermann & Petermann, 2010); ESPRIT-WHO-QUOL, Questionnaire World Health Organization 
Quality of Life (TheWhoqolGroup, 1998); FKK, Germen Questionnaire on Competence- and Control-beliefs (Krampen, 1991); FROGS, Functional 
Remission of General Schizophrenia (Llorca et al., 2009); GFS/GFR, Global Functioning Scale: Social and Global Functioning: Role (Cornblatt et 
al., 2007; Morosini et al., 2000); ISK-K, Inventory of Social Competencies-short version (Kanning, 2009); ISMI, Internalized Stigma of Mental Illness 
Scale (Sibitz et al., 2013); MASC, Movie for the Assessment of Social Cognition (Dziobek et al., 2007; Montag et al., 2011); M.I.N.I 6.0, Mini 
International Neuropsychiatric Interview (Sheehan et al., 2010); MRI, magnetic resonance imaging; MRS, Magnetic resonance spectroscopy; MRV, 
Mannheim Service Use Questionnaire (Salize & Kilian, 2010); MWT-B, Multiple Choice Word Test-B (Lehrl, 1999); NFCS, Need for Closure Scale-
16 (Schlink & Walther, 2007); PATHEV, Patient Questionnaire on Therapy Expectations and Evaluation (Schulte, 2005); PoFa, Picture of Facial 
Affect Test (Bölte et al., 2002); RdOc, Research Domain Criteria; RSA, Resilience Scale for Adults (Resnick & Inguito, 2011); SAT-MC, Social 
Attribution Test-multiple choice (Bell et al., 2010); SIPS, Structured Interview of Prodromal Syndromes (McGlashan et al., 2010); SPI-A, 
Schizophrenia Proneness Instrument – Adult Version (Schultze-Lutter et al., 2007); SOFAS, Social Functioning Assessment Scale (APA, 2000); 
TMT A & B, Trial Making Test A & B (Raitan, 1985); TPA, Top Problem Assessment (Weisz et al., 2012); UKU side-effect rating scale (Lindström et 
al., 2009).  
Note: 1 During intervention +/- 4 days, during follow-up +/- 2 weeks, deviations from starting date don’t sum up; 2 In case of suspected pregnancy;  
3 Additionally, if transition assessment positive (SIPS 5.0 P-Scale). 
TABLE 2. Inclusion, exclusion and withdrawal criteria of the study 
Inclusion criteria 
1. Age between 18 and 40 years; 
2. Subjects with the ability to follow study-instructions and to attend as well as complete 
all required visits; 
3. Written informed consent of the subject; 
4. Clinical High Risk Criteria 
- ESPRIT Ultra-high risk-(UHR) criteria (Attenuated positive symptoms and/or brief 
limited psychotic symptoms and/or a combination of familial risk or schizotypal 
disorder with a significant loss of functioning; severity assessed by the Structured 
Interview for Prodromal Syndromes, SIPS 5.0, McGlashan et al., 2010) and/or 
- The Basic Symptom Criterion ‘Cognitive disturbances’ (COGDIS) (2/9 cognitive-
perceptive basic symptoms; assessed by the Schizophrenia Proneness 
Instrument – Adult Version, SPI-A, Schultze-Lutter et al., 2004, 2006); 
 
Exclusion criteria 
Subjects will not be included in the study if any of the following criteria apply:  
1. Known history of hypersensitivity to the investigational drug or drugs with a similar 
chemical structure; 
2. Simultaneous participation in another clinical trial investigating medical products 
within 30 days prior to beginning of this clinical trial. Simultaneous participation in a 
non-interventional trial is permitted in case the subject is nevertheless willing and 
able to attend and complete in all required visits of the trial and in case there are no 
other contradictions; 
3. Subjects with a physical or psychiatric condition which at the investigator`s discretion  
may put the subject at other clinically significant risks than those defined as outcome 
of this study (i.e. development of a first-episode of psychosis, functional 
deterioration), may confound the trial results, or may interfere with the subject`s per 
protocol participation in this clinical trial; 
4. Suicidality in terms of subjects scoring higher than 0 on the Calgary Depression 
Scale for Schizophrenia (CDSS) item 8 on ‘suicidality’; 
5. Subjects with known substance abuse or dependency (DSM-IV-TR); 
6. Subjects with hepatic or renal failure; 
7. Subjects with known problems of galactose intolerance, clinically significant lactase 
deficiency or glucose-galactose malabsorption or histamine-intolerance of asthma 
bronchiale; 
8. Subjects with known asthma bronchiale; 
9. Subjects with a history of gastrointestinal ulcer; 
10. Intake of antitussives (cough-relieving agents); 
11. Intake of nitroglycerin; 
 
Exclusion criteria regarding special restrictions for females: 
12.  Current pregnancy or pregnancy planned within 9 months after start of medication 
or nursing women; 
13. Females of child-bearing potential, who are not using and not willing to use medically 
reliable methods of contraception for the entire study duration (such as oral, 
injectable or implantable contraceptives or intrauterine devices) unless they are 
surgically sterilized/hysterectomized or there are any other criteria considered 
sufficiently reliable by the investigator in individual cases; 
 
Indication specific exclusion criteria: 
14. Having had a psychotic episode for more than 1 week (according to SIPS 5.0);  
15. Having symptoms relevant for inclusion potentially arising from a known general 
medical disorder; 
16. Life-time antipsychotic medication for more than 30 days (cumulative number of 
days) at or above minimum dosage for a ‘first-episode of psychosis’ range according 
to current German treatment guidelines (exception: max. dosage for aripiprazole is 
5mg/d); 
17.  Any intake of antipsychotic medication (i.e. independent of duration of intake) within 
past three months before psychopathological baseline assessments (including self-
ratings and screening assessments) at or above minimum dosage of the ‘first-
episode of psychosis’ range according to current German treatment guidelines; 
18. Any intake of mood stabilizers (lithium, valproate, carbamazepine, oxcarbazepine, 
lamotrigine) for more than 30 days (cumulative number of days) during the past three 
months or any intake during the month before psychopathological baseline 
assessments (including self-ratings and screening assessments);  
19. Any past psychotherapeutic treatment specifically targeting psychotic symptoms or 
its prevention; 
 
Withdrawal criteria 
1. Investigator considers that because of safety, behavioural or administrative reasons, 
the subject needs to be excluded from the trial; Age between 18 and 40 years; 
2. New toxicological or pharmacological or severe adverse events occur that invalidate 
the earlier risk-benefit ratio; Written informed consent of the subject; 
3. Study-participant develops a manifest psychotic disorder (SIPS 5.0, McGlashan et 
al., 2010).  
 
 
 
TABLE 3. Content and intervention techniques of the Integrated Preventive Psychological Intervention (IPPI) 
Session 
number 
Target  
domain 
Intervention  
techniques 
1 Introduction 
Problems and 
Resources 
- Forming a therapeutic relationship 
- Exploration of current risk-symptoms and other mental health problems 
- Functionality of risk-symptoms for social environment and educational/job performance 
- Introduction of the intervention model and modules of the Integrated Preventive Psychological 
intervention (IPPI) 
- Elaboration of main difference between diagnosis and risk 
- Identification of main resources and problems of each individual 
2 
Explanation model 
and 
psychoeducation 
- Formulation of an individual explanation model for an at-risk state for psychosis  
- Linking individual risk-symptoms to the aims of IPPI and integrate them in overall intervention plan 
- Exploring possible misunderstandings and negative expectations related to the explanation model 
3-5 
Stress-
management 
- Repetition of explanation model 
- Linking stressors to risk-symptoms 
- Introduction of concepts and models of stress and coping 
- Identifying external/internal triggers of stress, functionality of stress and stress reactions of each 
individual  
- Exploring and providing feedback on the individual coping profile  
- Introduction and practice of the following coping-strategies: mindfulness, progressive muscle 
relaxation and setting priorities 
6-11 
Symptom-
management 
- Linking risk-symptoms to the individual explanation model  
- Normalising and validation of emotions related to risk-symptoms 
- Psychoeducation about different groups of risk-symptoms (basic symptoms, unusual and delusional 
thought contents, attenuated hallucinations and self-disturbances) by discussing current explanation 
models  
- Formulation of an individual explanation model of risk-symptoms including autobiographical aspects 
- Optimising and practising cognitive-behavioural strategies to reduce risk-symptoms (e.g. 
modification of stressors, cognitive biases and dysfunctional schema; generation of alternative 
explanations and experiments for reality testing) and emotion-focused strategies to deal with 
emotions triggered by risk-symptoms (e.g. anxiety, anger, depressiveness); cognitive remediation 
strategies to target deficits in selective attention and inhibition related to basic symptoms and 
aberrant salience processing 
12-15 Social cognition - 
Affect recognition 
- Optimising decoding of emotions including facial expressions, gesture and prosody based on 
exercises with increasing speed and intensity of emotions 
- Imitation of emotional expressions using a mirror 
- Computerised exercises to improve automatization of decoding processes 
16 Social cognition - 
Social perception 
- Identification and training of strategies to identify relevant social signals to interpret interpersonal 
situations with increasing complexity 
- Practising strategies based on a series of photos of social interactions to identify and use core 
social signals (e.g. distance, mutual affection, value of interaction, social roles) 
17 
Social cognition -
Theory of 
Mind/Empathy 
- Optimising and practising strategies to enhance theory of mind/empathy based on video-taped 
social interactions (e.g. to understand ironic messages) 
- Role-play of difficult social interactions to identify thoughts and feelings of others 
18-19 
Social cognition – 
Social attributions 
- Psychoeducation about common attribution biases (e.g. hostile attribution bias) 
- Linking attribution biases to deficits in theory of mind/empathy, one`s own self-concept and self-
stigma 
- Identification of cognitive, emotional and social consequences of attribution biases 
- Exploration of attribution styles based on case-vignettes and own attribution biases in everyday-life 
- Generation of alternative attributions 
20-22 
Social - Applying all learned social-cognitive strategies to complex social interactions  
- Discussing difficulties experienced when applying strategies in natural environment 
 problem-solving 
and booster-
session 
- Summarising intervention contents and most important resources and strategies of each individual 
FIGURE 1. Study design 
Note: ACC, N-Acetyl-Cysteine; IPPI, Integrated Preventive Psychological Intervention; PSM, 
Psychological Stress-Management; Plc, Placebo. 
 
